Bril Fernando相关文献与解析，生知库 | 链接生命科学的每一步

Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines

代谢性肝病：主要指南概述及改进未来指南的机会

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.70553

Improving MASLD Risk Stratification in Young Adults with Cardiometabolic Risk Factors and Insulin Resistance Assessment

改善具有心血管代谢风险因素和胰岛素抵抗评估的青年成人MASLD风险分层

期刊:Journal of the Endocrine Society

影响因子:3.1

doi:10.1210/jendso/bvaf209

Sharma, Anu; Godinez Leiva, Eddison; Kalavalapalli, Srilaxmi; Ortiz Rocha, Andrea; Cuervo-Pardo, Nathaly; Rosenberg, Jens; Bedossa, Pierre; Lomonaco, Romina; Bril, Fernando; Barb, Diana; Cusi, Kenneth

Role of Hepatic Glycogen on Nocturnal Gluconeogenesis in Type 2 Diabetes Mellitus

肝糖原在2型糖尿病夜间糖异生中的作用

期刊:Journal of Clinical Endocrinology & Metabolism

影响因子:5.1

doi:10.1210/clinem/dgaf044

Unni, Uma S; Bril, Fernando; Mugler, John P 3rd; Carter, Rickey E; Basu, Ananda; Basu, Rita

Will a "multivitamin" a day keep the "MASLD doctor" away?

每天服用“复合维生素”就能远离“MASLD医生”吗？

期刊:Metabolism and Target Organ Damage

影响因子:3.9

doi:10.20517/mtod.2025.24

Bril, Fernando

发表日期：2025

文献求助收藏

Prevalence of MASLD in People With Diabetes Has Decreased in the US, but Rates of Liver Fibrosis Are Still on the Rise

在美国，糖尿病患者中代谢相关肝病（MASLD）的患病率有所下降，但肝纤维化的发病率仍在上升。

期刊:Journal of the Endocrine Society

影响因子:3.1

doi:10.1210/jendso/bvaf110

Bril, Fernando; Bolla, Parameshwara; Huynh, Ky; Bobba, Sumedha

Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

代谢功能障碍相关脂肪肝患者血脂异常的实用管理方法

期刊:Journal of Lipid and Atherosclerosis

影响因子:

doi:10.12997/jla.2025.14.1.5

Bril, Fernando; Berg, Gabriela; Barchuk, Magali; Nogueira, Juan Patricio

Risk of Euglycemic Diabetic Ketoacidosis Can Persist After Discontinuation of Sodium-glucose Cotransporter-2 Inhibitors

停用钠-葡萄糖协同转运蛋白-2抑制剂后，正常血糖性糖尿病酮症酸中毒的风险可能持续存在

期刊:

影响因子:

doi:10.1210/jcemcr/luaf268

Bobba, Sai Sumedha; Campbell, Elizabeth; Bril, Fernando

Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants

即使存在PNPLA3变异体，胰岛素抵抗也是MASLD的一个固有特征。

期刊:Jhep Reports

影响因子:7.5

doi:10.1016/j.jhepr.2024.101092

Bril, Fernando; Kalavalapalli, Srilaxmi; Lomonaco, Romina; Frye, Reginald; Godinez Leiva, Eddison; Cusi, Kenneth

Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?

胰高血糖素样肽-1受体激动剂与1型糖尿病：潜在的变革者？

期刊:Frontiers in Endocrinology

影响因子:4.6

doi:10.3389/fendo.2024.1520313

Resnick, Ortal; Bril, Fernando; Beauchamp, Giovanna

Liver Stiffness Measurement and All-Cause Mortality in Individuals With Diabetes

肝脏硬度测量与糖尿病患者全因死亡率的关系

Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines

代谢性肝病：主要指南概述及改进未来指南的机会

Improving MASLD Risk Stratification in Young Adults with Cardiometabolic Risk Factors and Insulin Resistance Assessment

改善具有心血管代谢风险因素和胰岛素抵抗评估的青年成人MASLD风险分层

Role of Hepatic Glycogen on Nocturnal Gluconeogenesis in Type 2 Diabetes Mellitus

肝糖原在2型糖尿病夜间糖异生中的作用

Will a "multivitamin" a day keep the "MASLD doctor" away?

每天服用“复合维生素”就能远离“MASLD医生”吗？

Prevalence of MASLD in People With Diabetes Has Decreased in the US, but Rates of Liver Fibrosis Are Still on the Rise

在美国，糖尿病患者中代谢相关肝病（MASLD）的患病率有所下降，但肝纤维化的发病率仍在上升。

Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

代谢功能障碍相关脂肪肝患者血脂异常的实用管理方法

Risk of Euglycemic Diabetic Ketoacidosis Can Persist After Discontinuation of Sodium-glucose Cotransporter-2 Inhibitors

停用钠-葡萄糖协同转运蛋白-2抑制剂后，正常血糖性糖尿病酮症酸中毒的风险可能持续存在

Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants

即使存在PNPLA3变异体，胰岛素抵抗也是MASLD的一个固有特征。

Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?

胰高血糖素样肽-1受体激动剂与1型糖尿病：潜在的变革者？